Phospholipase A2 inhibitors or platelet-activating factor antagonists prevent prion replication

Area of Science:

• Neuroscience
• Biochemistry
• Pharmacology

Background:

• Prion diseases involve the conversion of cellular prion protein (PrP(C)) to disease-related isoforms (PrP(Sc)).
• Prion protein deposition is linked to neurodegeneration in prion diseases.
• Understanding the metabolic pathways of PrP(res) formation is crucial for developing therapeutic strategies.

Purpose of the Study:

• To investigate the role of phospholipase A(2) (PLA(2)) and platelet-activating factor (PAF) in the formation of protease-resistant PrP (PrP(res)).
• To evaluate the potential of PLA(2) inhibitors and PAF antagonists as therapeutic agents for prion diseases.

Main Methods:

• Pharmacological treatment of prion-infected cell lines (ScN2a, SMB, ScGT1) with PLA(2) inhibitors, glucocorticoids, and PAF antagonists.
• Assessment of PrP(res) accumulation and infectivity in treated cells.
• Investigation of the effect of PLA(2) inhibitors and PAF antagonists on PrP(C) levels in non-infected cells.

Main Results:

• Daily treatment with PLA(2) inhibitors prevented PrP(res) accumulation in infected cells.
• Glucocorticoids with anti-PLA(2) activity and PAF antagonists reduced PrP(res) levels and infectivity.
• Reversal of PLA(2) inhibitor effects by PAF addition indicated a role for PAF.
• Long-term treatment prevented detectable PrP(res) even after 12 weeks.
• PLA(2) inhibitors and PAF antagonists reduced PrP(C) levels in non-infected cells.

Conclusions:

• PLA(2) and PAF play a pivotal role in controlling PrP(res) formation.
• PLA(2) inhibitors and PAF antagonists show potential as therapeutic agents for prion diseases.
• Limiting cellular PrP(C) may be a strategy to restrict prion formation.